News Orexo AB

Stocks

ORX

SE0000736415

Pharmaceuticals

Market Closed - Nasdaq Stockholm 13:00:00 2026-10-28 EDT			5-day change	1st Jan Change
4.715 ^SEK	-3.38%		-11.87%	-84.34%

10-23	27 stocks have hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
10-23	Orexo - CEO interview with Nikolaj Sørensen about latest quarterly report	FW

All News

Mentions Relevance

10-23	Orexo - CEO interview with Nikolaj Sørensen about latest quarterly report	FW
10-22	Orexo AB, Nine Months 2026 Earnings Call, Oct 22, 2026
10-22	Orexo AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
10-22	Orexo's operating loss widened, CEO highlights progress in development pipeline and expects lower costs	FW
10-14	Orexo reports promising results for oral semaglutide tablet	FW
10-14	Orexo : reports encouraging bioavailability in first in vivo study of oral semaglutide formulation based on AmorphOX	PU
10-14	Orexo AB (Publ.) Reports Promising Initial Results from First Preclinical Pharmacokinetic in Vivo Study of Oral Semaglutide Tablet Based on Amorphox® Technology	CI
10-06	CEO interview with Nikolaj Sørensen at Orexo ahead of the upcoming offering	FW
10-06	Orexo: Withdrawing fair value range	AQ
10-06	Orexo Plans SEK250 Million Rights Issue to Fund Drug Development	MT
10-06	Orexo seeks to raise SEK 250m in offering	FW
10-06	Notice of Extraordinary General Meeting of Orexo	AQ
10-06	Orexo resolves on a rights issue of approximately 250 MSEK subject to approval by an extraordinary general meeting and provides a financial update	AQ
09-30	Orexo Submits Revised US FDA New Drug Application for Opioid Overdose Drug	MT
09-29	Orexo resubmits FDA application for Izipry	FW
09-29	Orexo Resubmits Application for Izipry to FDA	FW
09-29	Orexo resubmits NDA for IZIPRY™ to the FDA, a high-dose rescue medication for opioid overdose	AQ
09-29	Orexo AB (publ.) Resubmits NDA For IZIPRY To The FDA	CI
09-14	Orexo: FDA clearance to start pivotal programme	AQ
09-14	US Regulator Accepts Orexo's New Drug Application for Anaphylaxis Treatment	MT
09-14	Orexo receives FDA approval for IND application for OX640	FW
09-14	Orexo Announces FDA Acceptance Of Investigational New Drug Application For OX640 For The Treatment Of Anaphylaxis	CI
09-10	Orexo Secures Additional $3 Million Funding for Opioid Overdose Rescue Medicine	MT
09-10	Orexo gets an additional $3m from BARDA for OX390	FW
09-10	BARDA Supports Contract Modification extending the initial Development stage for the OX390 project to end of 2027	AQ